Abstract 1621: L105, a next generation of Bcl-2 inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1621
Abstract: Background: The Bcl-2 inhibitor venetoclax is approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). However, disease progression occurs when Ventoclax long-term treatment as a single… read more here.
Keywords: l105; bcl inhibitor; venetoclax; next generation ... See more keywords